secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0000950170-23-037162
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO Q2 net loss $72.1M ($1.66/sh); revenue $20M; RGX-121 enrollment complete
--------------------------------------------------------------------------------

- Net loss widened to $72.1M vs $68.2M YoY; diluted EPS -$1.66.
- Revenue fell to $20.0M from $32.6M; Zolgensma royalty revenue down to $19.0M.
- Cash, equivalents and marketable securities $415.4M; runway into 2025.
- Completed enrollment (10 patients) in Phase III CAMPSIITE trial for RGX-121; BLA filing planned 2024.
- ABBV-RGX-314 suprachoroidal dose level 3 with short-course steroids showed zero intraocular inflammation (N=39).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000095017023037162/0000950170-23-037162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000095017023037162/rgnx-20230802.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-037162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer